Dyslipidaemias and their treatment in high complexity centres in Colombia
Voir/ Ouvrir
Date
2020-05Les auteurs
Ruiz Morales, Alvaro JVargas-Uricoechea, Hernando
Urina-Triana, Miguel
Román-González, Alejandro
Isaza, Daniel
Etayo, Edwin
Quintero, Adalberto
Molina, Dora Inés
Toro, Juan Manuel
Parra, Gustavo
Merchán, Alonso
Cadena, Alberto
Yupanqui Lozano, Hernán
Cárdenas, Juan Mauricio
Quintero, Álvaro Mauricio
Botero, Rodrigo
Jaramillo, Mónica
Arteaga, Juan Manuel
Vesga-Angarita, Boris
Vesga-Angarita, Etna
Betancur-Valencia, Mónica
Auteur(s) d'entreprise
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
Type
Artículo de revista
ISSN
0214-9168
Partager cet enregistrement
Citación
Metadata
Afficher la notice complète
Documents PDF
Titre anglais
Dyslipidaemias and their treatment in high complexity centres in ColombiaAbstrait
Background and objective
Data is scarce on the distribution of different types of dyslipidaemia in Colombia. The primary objective was to describe the frequency of dyslipidaemias. The secondary objectives were: frequency of cardiovascular comorbidity, statins and other lipid-lowering drugs use, frequency of statins intolerance, percentage of patients achieving c-LDL goals, and distribution of cardiovascular risk (CVR).
Materials and methods
Cross-sectional study with retrospective data collection from 461 patients diagnosed with dyslipidaemia and treated in 17 highly specialised centres distributed into six geographic and economic regions of Colombia.
Results
Mean (SD) age was 66.4 (±12.3) years and 53.4% (246) were women. Dyslipidaemias were distributed as follows in order of frequency: mixed dyslipidaemia (51.4%), hypercholesterolaemia (41.0%), hypertriglyceridaemia (5.4%), familial hypercholesterolaemia (3.3%), and low c-HDL (0.7%). The most prescribed drugs were atorvastatin (75.7%) followed by rosuvastatin (24.9%). As for lipid control, 55% of all patients, and 28.6% of those with coronary heart disease, did not achieve their personal c-LDL goal despite treatment. The frequency of statin intolerance was 2.6% in this study.
Conclusions
Mixed dyslipidaemia and hypercholesterolaemia are the most frequent dyslipidaemias in Colombia. A notable percentage of patients under treatment with lipid-lowering drugs, including those with coronary heart disease, did not achieve specific c-LDL goals. This poor lipid control may worsen patient's CVR, so that therapeutic strategies need to be changed, either with statin intensification or addition of new drugs in patients with higher CVR.
Keywords
AtherosclerosisCardiovascular disease
Dyslipidaemia
Statins
Familial hypercholesterolaeima
Lien vers la ressource
https://www.elsevier.es/en-revista-clinica-e-investigacion-arteriosclerosis-english-415-articulo-dyslipidaemias-their-treatment-in-high-S2529912320300309Origine
Clínica e Investigación en Arteriosclerosis; Volumen 32 Número 3 , Páginas 101 - 110 (2020)
Google Analytics Statistics
Collections
- Artículos [682]